Tesamorelin
FDA-Approved GHRH Analog
Tesamorelin is a stabilized 44-amino-acid GHRH analog, modified at residue 3 to resist enzymatic degradation. FDA-approved as Egrifta for HIV-associated lipodystrophy, it remains one of the most clinically characterized GHRH analogs. Studied extensively for somatotropic axis modulation and visceral adipose tissue regulation in preclinical and clinical models. For laboratory research use only.
Binds the pituitary GHRH receptor (GHRHR), stimulating endogenous growth hormone secretion via cAMP/PKA signaling while preserving physiological pulsatility.
For Research Use Only. Sold for in vitro laboratory research. Not for human or veterinary consumption. By purchasing, you confirm you are 21+ and a qualified research professional.
44-residue stabilized GHRH analog (Trans-3-hexenoyl modification at N-terminus).
Every batch of Tesamorelin ships with an independently conducted Certificate of Analysis by Janoshik Analytical or Bioviridian. The COA includes HPLC-MS chromatogram, mass spec confirmation, endotoxin levels, and heavy metals screening.
Batch number is printed on the vial label and included in your order confirmation email. Look it up at pepidyn.com/coa.
